Evaluation of 24-hour intragastric pH using esomeprazole, lansoprazole, and pantoprazole in Hispanic patients with GERD

Study identifier:D9612L00106

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients with Symptomatic GERD

Medical condition

Gastroesophageal Reflux Disease

Phase

Phase 4

Healthy volunteers

No

Study drug

Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg

Sex

All

Actual Enrollment

90

Study type

Interventional

Age

18 Years - 69 Years

Date

Study Start Date: 01 Oct 2006
Primary Completion Date: -
Study Completion Date: 01 May 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria